Prevalence of anti-TNF contraindications in Crohn's disease: A cross-sectional survey from the GETAID
Aurélien Amiot(Université Paris-Est Créteil), Xavier Tréton(Hôpital Beaujon), Mathieu Uzzan(Université Paris-Est Créteil), Anne Bourrier, Laurent Beaugerie(Assistance Publique – Hôpitaux de Paris), Ginette Fotsing, Mélanie Serrero(Assistance Publique Hôpitaux de Marseille), Charlotte Gagnière, Guillaume Bouguen(Inserm), Carole Martins, Julien Kirchgesner(Université Paris-Est Créteil), Harry Sokol(AgroParisTech), Yoram Bouhnik(Centre Hospitalier Universitaire de Saint-Étienne), Cecilia Landmann, Carmen Stefănescu(Centre Hospitalier Universitaire de Saint-Étienne), Émilie Del Tedesco(Nutrition-Génétique et Exposition aux Risques Environnementaux), Laurianne Plastaras(Hôpital Pasteur), David Laharie(Université de Bordeaux), Pauline Wils(Hôpital Claude Huriez)
Cited by 1
Related Papers
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Potential of fecal microbiota for early‐stage detection of colorectal cancer
|Molecular Systems Biology|2014|1.4k
ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment
|Journal of Crohn s and Colitis|2019|1.4k